ArticleHepatology (Baltimore, Md.)2021
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.
Article in Hepatology (Baltimore, Md.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Prevention, surveillance, and early detection of hepatocellular carcinoma - a Brazilian multidisciplinary consensus.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026Guideline
- The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis.Abdominal radiology (New York) · 2022Pooled it
- Diagnostic Performance of Transient Elastography Versus Two-Dimensional Shear Wave Elastography for Liver Fibrosis in Chronic Viral Hepatitis: Direct Comparison and a Meta-Analysis.BioMed research international · 2022Pooled it
- Longitudinal Adherence to Hepatocellular Carcinoma Surveillance and Associated Outcomes Following Ultrasound Liver Imaging Reporting and Data System (US LI-RADS) Implementation.Digestive diseases and sciences · 2026Article
- Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in US Individuals With Chronic Hepatitis B Virus Infection.Journal of viral hepatitis · 2026Article
- Long-term outcomes of baseline grey-zone patients with HBeAg-negative chronic hepatitis B virus infection.JHEP reports : innovation in hepatology · 2026Article
- Clinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure.Journal of viral hepatitis · 2025Article
- Chronic hepatitis B: Is it time for expanded antiviral treatment?World journal of virology · 2025Review
- Disparities in Social Vulnerability and Premature Mortality among Decedents with Hepatitis B, United States, 2010-2019.Journal of racial and ethnic health disparities · 2025Article
- Assessing pricing and affordability of HBV treatment in Asia-Pacific region: a barrier to elimination.Hepatology international · 2025Article
- IL-2 and IL-15 augment HBV therapeutic vaccination and PD1 blockade for functional cure in the AAV-HBV mouse model.Frontiers in immunology · 2025Article
- Cost-effectiveness analysis of oral antiviral therapy in patients with indeterminate chronic hepatitis B infection.Translational gastroenterology and hepatology · 2025Article
- Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: 'Progress toward hepatitis B elimination in Canada'.Canadian liver journal · 2024Article
- Hepatitis B Care Continuum Models-Data to Inform Public Health Action.Public health reports (Washington, D.C. : 1974) · 2024Review
- Global burden of hepatitis B virus: current status, missed opportunities and a call for action.Nature reviews. Gastroenterology & hepatology · 2023Review
- Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Article
- Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of disease.Journal of gastroenterology and hepatology · 2023Article
- Racial Disparities in Treatment Initiation and Outcomes of Chronic Hepatitis B Virus Infection in North America.JAMA network open · 2023Observational
- Viral Hepatitis Among African Immigrants with Hepatocellular Carcinoma in Minnesota: High Prevalence Yet Low Awareness.Journal of immigrant and minority health · 2023Article
- Liver Complications in Untreated Treatment-Ineligible versus Treated Treatment-Eligible Patients with Hepatitis B.Digestive diseases (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 13 institutions in 3 countries.
Funding
Abstract
BACKGROUND AND
aimsOutcomes of persons with chronic hepatitis B virus (HBV) infection in the era of antiviral therapy (AVT) are not well characterized. We determined the incidence and factors associated with clinical outcomes in a multiethnic, North American cohort of adults with chronic HBV infection, who were not on AVT at enrollment. APPROACH AND
resultsAdults with chronic HBV infection, not receiving AVT, and without a history of decompensation, HCC, or liver transplantation (LT), were prospectively followed. Participants with known human immunodeficiency virus (HIV), hepatitis C virus, or hepatitis D virus (HDV) coinfection were excluded. During follow-up, treatment could be initiated per standard of care. Clinical outcomes included: incident cirrhosis, decompensation, HCC, OLT, and HBV-related death. Among 1,418 participants analyzed, 51.5% were women, median age was 41.1 years, 75% were Asian, 10% White, 13% Black, 24% HBeAg(+), and 1.5% cirrhosis at baseline. During the study, 274 started treatment, 83 had an alanine aminotransferase flare, 118 of 330 initially HBeAg(+) became HBeAg(-), and 90 of 1,329 became HBsAg(-). After 6,641 person-years follow-up, 8 participants (4 of 21 with baseline cirrhosis) had 12 clinical outcomes (2 decompensation, 5 HCC, 2 OLT, and 3 HBV-related deaths) and 19 of 1,397 had incident cirrhosis. Twenty-one of 26 participants had first outcome before treatment, none had become HBsAg(-), whereas 5/9 HBeAg(+) had become HBeAg(-) at time of first outcome. Cumulative percentage of clinical outcomes was 16% at year 4 in participants with baseline cirrhosis and 2% (including incident cirrhosis) at year 7 in those without.
conclusionsIncidence of adverse outcomes was low in this closely monitored, large cohort of North American adults with predominantly inactive, chronic HBV without cirrhosis. Our data highlight the benefits of HBsAg loss and the importance of early diagnosis and treatment to prevent cirrhosis and other complications of chronic HBV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.